Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo
Matthias Scheiner, Dominik Dolles, Sandra Gunesch, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 20, pp. 9078-9102
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 127
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism
Shuaishuai Xing, Qi Li, Baichen Xiong, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 2, pp. 858-901
Closed Access | Times Cited: 73
Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Giulia Abate, Daniela Uberti, Simone Tambaro
Biology (2021) Vol. 10, Iss. 6, pp. 542-542
Open Access | Times Cited: 71
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Siew Lee Cheong, Jian Kai Tiew, Yi Hang Fong, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1560-1560
Open Access | Times Cited: 45
New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands
Tian‐Yu Sun, Tengfei Zhen, Chrisanta Hamis Harakandi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116569-116569
Closed Access | Times Cited: 11
Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice
Elisabet Viayna, Nicolas Coquelle, Monika Cieslikiewicz‐Bouet, et al.
Journal of Medicinal Chemistry (2020) Vol. 64, Iss. 1, pp. 812-839
Open Access | Times Cited: 67
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model
Feng He, C. James Chou, Matthias Scheiner, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3794-3812
Open Access | Times Cited: 49
Visible‐Light Photoswitchable Benzimidazole Azo‐Arenes as β‐Arrestin2‐Biased Selective Cannabinoid 2 Receptor Agonists
Sophie A. M. Steinmüller, Julia Fender, Marie H. Deventer, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 49
Open Access | Times Cited: 21
Benzimidazole and Benzoxazole Derivatives Against Alzheimer's Disease
Nagihan Faydalı, Özlem Temiz‐Arpacı
Chemistry & Biodiversity (2024) Vol. 21, Iss. 6
Closed Access | Times Cited: 6
Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer’s Disease Mouse Model
Matthias Scheiner, Matthias Hoffmann, Feng He, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 9302-9320
Closed Access | Times Cited: 40
A ratiometric near-infrared fluorescent probe based on a novel reactive cyanine platform for mitochondrial pH detection
Shulin Wan, Shuai Xia, Jerry Medford, et al.
Journal of Materials Chemistry B (2021) Vol. 9, Iss. 25, pp. 5150-5161
Open Access | Times Cited: 35
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
Philipp Spatz, Sophie A. M. Steinmüller, Anna Tutov, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6414-6435
Open Access | Times Cited: 14
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents
Geoffrey Canet, Charleine Zussy, Célia Hernandez, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108398-108398
Open Access | Times Cited: 13
Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration
Giuseppe Felice Mangiatordi, Francesca Intranuovo, Pietro Delre, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14448-14469
Closed Access | Times Cited: 34
In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor
Asma Gholami, Dariush Minai‐Tehrani, Leif A. Eriksson
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6
F. Javier Pérez-Areales, María Garrido, Ester Aso, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 9360-9390
Open Access | Times Cited: 31
Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo
Julian Hofmann, Shaimaa Fayez, Matthias Scheiner, et al.
Chemistry - A European Journal (2020) Vol. 26, Iss. 32, pp. 7299-7308
Open Access | Times Cited: 30
SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria
Eman M.E. Dokla, Nader S. Abutaleb, Sandra N. Milik, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115040-115040
Open Access | Times Cited: 16
Cannabidiol repairs behavioral and brain disturbances in a model of fetal alcohol spectrum disorder
Ani Gasparyan, Daniela Navarro, Francisco Navarrete, et al.
Pharmacological Research (2023) Vol. 188, pp. 106655-106655
Open Access | Times Cited: 10
Novel Dual-Acting Hybrids Targeting Type-2 Cannabinoid Receptors and Cholinesterase Activity Show Neuroprotective Effects In Vitro and Amelioration of Cognitive Impairment In Vivo
Claudia Mugnaini, Antonella Brizzi, Marco Paolino, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 5, pp. 955-971
Closed Access | Times Cited: 3
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)
Miroslav Kosar, Leonard Mach, Erick M. Carreira, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 665-700
Closed Access | Times Cited: 3
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
Hongguang Ma, Boshi Huang, Yan Zhang
Drug Discovery Today (2020) Vol. 25, Iss. 9, pp. 1682-1692
Open Access | Times Cited: 26
Discovery of multifunctional anti-Alzheimer’s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters
Anna Pasieka, Dawid Panek, Jakub Jończyk, et al.
European Journal of Medicinal Chemistry (2021) Vol. 218, pp. 113397-113397
Closed Access | Times Cited: 19
Novel benzimidazole-based pseudo-irreversible butyrylcholinesterase inhibitors with neuroprotective activity in an Alzheimer's disease mouse model
Philipp Spatz, Thomas Zimmermann, Sophie A. M. Steinmüller, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 8, pp. 944-954
Open Access | Times Cited: 13
Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain
Jinshan Nan, Jingming Liu, Guifeng Lin, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3460-3483
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top